Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Iodine-131 Anti-B1 Antibody
Bexxar · 2 trials · 3 indications
| Arm | Type | Description |
|---|---|---|
| Treatment, Non-Randomized, Open Label | EXPERIMENTAL | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
| Name | Type | Description |
|---|---|---|
| Bexxar | DRUG | Day 0: Tositumomab, IV (in the vein) followed by test dose of 131I-Tositumomab, IV (in the vein) to determine treatment dose of 131I-Tositumomab. 1-2 weeks after Day 0: Tositumomab, IV (in the vein) followed by therapeutic dose 131I-Tositumomab (in the vein). |
| Iodine-131 Anti-B1 Antibody | BIOLOGICAL | Dosimetric Dose: 450 mg unlabeled Anti-B1 Antibody infused over 1 hour or longer followed by 35 mg of Anti-B1 Antibody of which 1-2 mg has been labeled with 5 mCi of Iodine-131 infused over 20 minutes. Therapeutic Dose: 7-14 days after dosimetric dose, 450 mg Anti-B1 Antibody infused over 1 hour or longer followed by 35 mg of Anti-B1 Antibody labeled with the subject-specific dose of Iodine-131 to deliver the desired total body radiation, infused over 20 minutes The dose escalation will be initiated at 45 cGy and will be increased in 10 cGy increments until the maximum tolerated dose (MTD) is reached. |
Inclusion Criteria: * CD20 positive B-cell lymphoma * Confirmed relapsed/refractory disease following autologous transplant * Age ≤ 75 years * Performance status 0 or 1 * Creatinine ≤ 1.5 or calculated creatinine clearance ≥ 60 ml/min * Total bilirubin, AST, and ALT ≤ 1.5 x upper limit of normal (u...
Top 1 of 2 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Incyte Corporation | INCY | 1 | PHASE2 | Ruxolitinib |